Dear Investors:

Thank you for visiting the Anika Therapeutics investor relations website. We’ve designed the site to provide quick access to the latest corporate information, as well as insight into our products, strategies and growth prospects.

Anika’s achievements in 2010 provide a platform for future success in 2011.  Our flagship Orthobiologics product Orthovisc® – a multiple injection regimen for treating osteoarthritis of the knee – continues to gain share in this segment of the market. Sales of Monovisc™ – our single injection Orthobiologics product currently marketed in Europe – more than doubled in 2010 and continue to grow. In addition, the advanced wound care, surgical and orthopedic products we acquired with Fidia Advanced Biopolymers, S.r.l., now renamed Anika Therapeutics S.r.l., have added depth and breadth to our revenue base.

This is an exciting time for Anika. I invite you to return to our website frequently for updates on our accomplishments.


Charles H. Sherwood, Ph.D.
President & Chief Executive Officer
Safe Harbor

This web site contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include without limitation, statements that may be identified by words such as “expectations," “remains," “focus," “expected," “prospective," “expanding," “building," “continue," “progress," “efforts," “hope," “believe," “objectives," “opportunities," “will," “seek," and other expressions which are predictions of or indicate future events and trends and which do not constitute historical matters identify forward-looking statements. The statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and other factors. The Company's actual results could differ materially from any anticipated future results, performance or achievements described in the forward-looking statements as a result of a number of factors including: the Company's ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all, obtain clinical data to support a pre-market approval application and/or FDA approval, and/or receive FDA or other regulatory approvals of its products, or that such approvals will not be obtained in a timely manner or without the need for additional clinical trials; and the results of its research and product development efforts and their relative success and timing of regulatory approvals; and commercialization of the Company's products. Certain other factors that might cause the Company's actual results to differ materially from those in the forward-looking statements include those set forth under the headings "Business," "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in each of the Company's Annual Report on Form 10-K for the year ended December 31, 2010.